Dynamic interaction between fetal adversity and a genetic score reflecting dopamine function on developmental outcomes at 36 months

Adrianne R. Bischoff, Irina Pokhvisneva, Étienne Léger, Meir Steiner, James L. Kennedy, Kieran J. O’Donnell, Josie Diorio, Michael J. Meaney, Patricia P. Silveira*, on behalf of the MAVAN research team

1 Department of Pediatrics, Division of Neonatology, University of Toronto and the Hospital for Sick Children, Toronto, Ontario, Canada, 2 Ludmer Centre for Neuroinformatics and Mental Health, Douglas Mental Health University Institute, McGill University, Douglas Mental Health University Institute, Montreal, Québec, Canada, 3 Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada, 4 Department of Psychiatry, University of Toronto and Centre for Addiction and Mental Health, Toronto, Ontario, Canada, 5 Child and Brain Development Program, Canadian Institute for Advanced Research (CIFAR), Toronto, Ontario, Canada, 6 Department of Psychiatry, McGill University, Montreal, Québec, Canada

¶ The complete membership of the author group can be found in the Acknowledgments.

* patricia.silveira@doctors.mcgill.ca

Abstract

Background

Fetal adversity, evidenced by poor fetal growth for instance, is associated with increased risk for several diseases later in life. Classical cut-offs to characterize small (SGA) and large for gestational age (LGA) newborns are used to define long term vulnerability. We aimed at exploring the possible dynamism of different birth weight cut-offs in defining vulnerability in developmental outcomes (through the Bayley Scales of Infant and Toddler Development), using the example of a gene vs. fetal adversity interaction considering gene choices based on functional relevance to the studied outcome.

Methods

36-month-old children from an established prospective birth cohort (Maternal Adversity, Vulnerability, and Neurodevelopment) were classified according to birth weight ratio (BWR) (SGA ≤0.85, LGA >1.15, exploring a wide range of other cut-offs) and genotyped for polymorphisms associated with dopamine signaling (TaqIA-A1 allele, DRD2-141C Ins/Ins, DRD4 7-repeat, DAT1-10- repeat, Met/Met-COMT), composing a score based on the described function, in which hypofunctional variants received lower scores.

Results

There were 251 children (123 girls and 128 boys). Using the classic cut-offs (0.85 and 1.15), there were no statistically significant interactions between the neonatal groups and the
dopamine genetic score. However, when changing the cut-offs, it is possible to see ranges of BWR that could be associated with vulnerability to poorer development according to the variation in the dopamine function.

**Conclusion**

The classic birth weight cut-offs to define SGA and LGA newborns should be seen with caution, as depending on the outcome in question, the protocols for long-term follow up could be either too inclusive—therefore most costly, or unable to screen true vulnerabilities—and therefore ineffective to establish early interventions and primary prevention.

**Introduction**

The Developmental Origins of Health and Disease (DOHaD) concept explores the idea that variations in the quality of the early environment influence the risk for developing chronic health conditions over the life course [1, 2]. One marker of fetal adversity is poor fetal growth; being born small for gestational age (SGA) is associated with increased risk for several diseases later in life, including a wide range of metabolic [3–5] as well as mental health outcomes [6–9]. More recently, large for gestational age (LGA) newborns were also identified as being at long-term risk for developing metabolic syndrome [10] and psychopathology [11–13].

Despite the several above-described association studies, it is still challenging to clearly define which newborns are at risk for developing chronic diseases, who should be followed closely during childhood, and which are the specific risks. The classical 10th percentile cut-off for birth weight at a given gestational age is somewhat arbitrary to define vulnerability in general, and may even be variable according to the evaluated outcome. Similarly, the well described “inverted U shape” association that characterizes the relationship between birth weight and later disease risk [16] suggests that the correlations between birth weight and vulnerability are not linear. It is intriguing to think that the inflection points for the inverted “U” could vary depending on the outcomes studied. In other words, the optimal birth weight for avoiding later metabolic risk may not be the same as the optimal birth weight for better developmental outcomes, for instance.

Using the classic cut-offs, SGA is associated with poorer developmental scores in children from 6 to 36 months [17–19]. A systematic review by Levine et al. identified that the most common developmental outcomes associated with poor fetal growth were motor, cognitive and language delays [17]. Reduced adaptive behavior skills have also been reported [20]. The burden becomes even more significant when acknowledging that impaired fetal growth is also associated with worse long term outcomes such as lower educational achievement and economic status in adulthood [21]. Maternal obesity, a known factor associated with both SGA and LGA births, has also been linked to behavioral difficulties and attention-deficit hyperactive disorder (ADHD) in the offspring [22]. Similarly, relationships between being born LGA and later developmental disorders have been described [23].

An interesting neurobiological target that plays a role in many of these domains is dopamine (DA). This neurotransmitter is involved in reinforcement/reward [24], learning [25, 26] and motor development [25]. For instance, genetic variations on different components of the dopaminergic system are associated with mental health diseases such as ADHD [27], obsessive compulsive disorder [28] and schizophrenia [29]. In rodents, it was shown that a selective destruction of DA terminals or the blockade of cortical DA receptors impair motor learning,
while not affecting the execution of a previously acquired skill [30]. Moreover, natural genetic variation in the number of mesocortical dopamine neurons or expression of DA-related genes in the cortex seem to explain interindividual differences in motor learning in mice [31]. There are also studies linking specific polymorphisms of the dopamine receptor type 2 (DRD2) to variation in developmental scores in children [32] as well as to verbal fluency, cognitive flexibility and creativity [33, 34], suggesting that dopamine is involved in all main domains of neurodevelopment (motor skills, language, behavioral modulation, cognition and problem solving). Interestingly, experimental studies have shown that variations in fetal growth modify DA synthesis, expression and metabolism at different structures of the mesocorticolimbic system [35–37].

Different studies have explored dopamine-related genes in a candidate-gene approach, and several examples show that genetic variation in these genes is associated with cognitive diversity. For instance, the COMT gene encodes an enzyme that regulates central dopamine catabolism; variations on this gene such as the COMT Val158Met are related to differences in working memory and high order cognitive processing [38, 39]. Genetic polymorphisms found on the dopamine type 2 receptor gene (DRD2 gene, rs1799732 [−141delC]) or its regulators (rs1800497 [Taq1A]) were linked to cognitive performance [40] and to ADHD core traits and co-morbidity [41]. Similarly, DRD4 exon III VNTR has been implicated in the development of ADHD and impulsivity [42, 43], and dopamine transporter (DAT1 gene) VNTR has been related to cognitive flexibility[44] and risk taking [45]. In this study, we aimed at using a multilocus approach, in which the genetic variation of these five important polymorphisms (rs1800497 [Taq1A], COMT Val158Met [rs4680], DRD2 rs1799732 [−141delC], DAT1 and DRD4 VNTRs) was considered at the same time. The score was calculated based on the described contribution that each gene variant has on dopamine signaling, so that hypofunctional variants received lower scores.

The objective of this study is to investigate the possible dynamism of birth weight cut-offs in defining vulnerability in different outcomes. For that, we explored an interaction between fetal adversity (SGA and LGA) and DA-relate genes (genetic score reflecting dopamine function), with gene choices based on known functional relevance to the studied outcome, as an example. Considering the important role of dopamine in multiple domains of development and the increased risk for SGA and LGA children to have abnormal developmental outcomes, we hypothesized that; a) birth weight moderates the association between the genetic score and development at 3 years of age; b) the moderating effect of birth weight on this association is specific to the evaluated domain and c) it varies with the different cut-offs defining SGA and LGA.

Methods

Individuals were selected from a prospective birth cohort (Maternal Adversity, Vulnerability and Neurodevelopment—MAVAN) [46]. The sample included children from Montreal (Quebec) and Hamilton (Ontario), Canada. Eligibility criteria for mothers included age ≥18 years, singleton pregnancy and fluency in French or English. Mothers were excluded from the study if they had severe chronic illness, placenta previa, a history of incompetent cervix, impending delivery, or had a fetus/infant born at gestational age <36 weeks or with a major anomaly. Mother and child dyads were assessed longitudinally both at home or in a laboratory setting across the child’s development. In this study, we used data from the developmental assessment done at 36 months (see below). Approval for the MAVAN project was obtained from obstetricians performing deliveries at the study hospitals and by the institutional review boards at hospitals and university affiliates: McGill University, l’Université de Montréal, the Royal Victoria
Hospital, Jewish General Hospital, Centre Hospitalier de l’Université de Montréal, Hôpital Maisonneuve-Rosemont, St Joseph’s Hospital, and McMaster University, Hamilton, Ontario, Canada. Informed consent was obtained from the parents/guardians of the participants.

SGA and LGA definitions
Birth weight ratio (BWR) is the ratio between the observed birth weight and the sex-specific mean birth weight for each gestational age for the local population [47]. This variable was used to split the sample into three groups: SGA, adequate for gestational age (AGA) and LGA as described in the Statistical Methods. For the sake of sample description, we used the classic cut-offs of BWR 0.85 and 1.15, which defined SGA and LGA groups and represent roughly 1 SD above and below the mean population birth weight. For the main analysis, these cut-offs were changed to investigate possible group differences observable in the association between the dopamine genetic score and the outcome (see details below).

Genetic data and multilocus score definition
Saliva samples were collected and genotyping of the DNA was performed. The ANKK1/DRD2 markers (rs1800497 [Taq1A]), COMT Val158Met (rs4680) SNP, DRD2 rs1799732 [−141delC], DAT1 and DRD4 VNTRs were amplified with polymerase chain reaction (PCR)–detailed methods are described elsewhere [48]. We followed the same approach proposed by Stice et al [49], using a multilocus genetic composite driven by the biological function. In this score, genotypes associated with putatively low DA signaling received a score of 0; those associated with high DA signaling received a score of 1; intermediate heterozygotes received a score of 0.5. Specifically, TaqIA A1/A1 [50], DRD2-141C Ins/Ins carriers [51], DRD4-7 repeat carriers [52], DAT1 10R/10R [53], and COMT Met/Met [54] genotypes were assigned a score of 0 (“low”); TaqIA A2/A2, DRD2-141C Del/Del carriers, DRD4 non 7-repeat carriers, DAT1 9/9 carriers, and COMT Val/Val genotypes were assigned a score of 1 (“high”), and DRD2-141C Ins/Del, TaqIA A1/A2, DAT 1 9/10 and COMT Met/Val genotypes received a score of 0.5. The sum of the scores resulted in a multilocus composite.

In terms of linkage disequilibrium, DAT 1 gene is located on chromosome 5, COMT gene is located on chromosome 22. The other 3 polymorphisms are from genes found on chromosome 11, but an analysis using LDlink for the two snps as well as rs762502 (a snp located at the exon 3 as a proxy for DRD4 VNTR) shows that both D prime and R squared have values close to 0, indicating independence/no linkage of alleles.

Developmental scores
Developmental outcomes were assessed using the Bayley Scales of Infant and Toddler Development II [55]. The evaluation was performed by experienced professionals within 4 months of the time point when the child reached 36 months. Three major areas of development were used in this study: Total Behavioral Rating Scale, Motor Developmental Index (PDI) (which includes fine and gross motor subtests) and Mental Developmental Index (MDI).

Statistical methods
To define three BWR groups, two cut-offs should be used: cut-off A defines the SGA group (subjects with BWR ≤ A), and cut-off B defines the LGA group (subjects with BWR > B). Subjects with a BWR between cut-offs A and B comprise the AGA group.

Sample baseline characteristics of the three groups (SGA, AGA, LGA) were compared using ANOVA test for continuous data and chi-square test for categorical variables. All
subjects with BWR $\leq 0.85$ were considered as SGA group, subjects with BWR $> 1.15$ were considered as LGA, and subjects with BWR in between 0.85 and 1.15 were referred to as AGA.

Fig 1 is a graphical representation of the scheme used to categorize BWR into three groups. For the main analysis, fixing a low cut-off A at a certain value (varying from 0.7 to 1.0), we iterated the high cut-off B (from 1.01 to 1.2) each time performing a linear regression analysis to investigate if the categorized BWR moderates the association between the dopamine genetic score.
score and each one of the three Bayley domains. Co-variates in every linear regression are categorized BWR, dopamine genetic score, their interaction and gender.

Data were analyzed using the Statistical Package for the Social Sciences (SPSS) 22.0 software (SPSS Inc., Chicago, IL, USA) and R[56]. Significance levels for all measures were set at $p < 0.05$.

**Results**

There were 251 individuals in the sample. Table 1 depicts the baseline characteristics, and no significant differences were found between the BWR groups.

Table 2 shows the genotype distribution for each gene, with the Hardy-Weinberg criteria met in all cases.

Table 3 describes the mean scores for the different Bayley domains in the three BWR groups. We show in Table 3 that, when using the classic cut-offs (0.85 and 1.15), there were no

| Table 1. Baseline characteristics. |
|-------------------------------------|
| **Sample characteristics** | **SGA (n = 52)** | **AGA (n = 178)** | **LGA (n = 21)** | **$P$ value** |
| Females (%)$^a$ | 27 (51.9%) | 85 (47.8%) | 11 (52.4%) | 0.83 |
| Maternal age at birth (%)$^b$ | 29.49(5.02) | 30.67(4.64) | 30.20(4.00) | 0.28 |
| Exclusive breastfeeding (weeks)$^b$ | 25.85(18.81) | 27.68(19.35) | 24.89(17.63) | 0.73 |
| Maternal smoking during gestation (%)$^a$ | 9 (20.5%) | 17 (10.7%) | 0 (0%) | 0.07 |
| Family income below LICO (%)$^a$ | 9 (17.3%) | 27 (16.4%) | 2 (10%) | 0.74 |
| Diabetes since the beginning of the pregnancy (%) | 1 (1.92%) | 5 (2.81%) | 1 (4.76%) | 0.63 |
| Number of full weeks of gestation | 39.27 (1.21) | 39.21 (1.17) | 38.67 (1.32) | 0.12 |
| C-section (%) | 9 (17.3%) | 33 (18.5%) | 8 (38.1%) | 0.09 |

$^a$Chi-square test and $^b$ANOVA test.

Data are expressed as Mean(SD) or number of participants (percentages). SGA = small for gestational age, AGA = adequate for gestational age, LGA = large for gestational age, LICO = Low Income Cut Off [57]. Small differences in totals are due to missing data.

https://doi.org/10.1371/journal.pone.0177344.t001

| Table 2. Genotype distribution in the study sample. |
|-------------------------------------|
| **Gene** | **Distribution** | **H-W equilibrium ($P$ value)** |
| DAT1 VNTR | 10/10 (133, 53%); 9/10 (96, 38%); 9/9 (22, 9%) | 0.44 |
| DRD2 141C (rs1799732) BstNI | Ins/Ins (189, 75%); Ins/Del (57, 23%); Del/Del (5, 2%) | 0.77 |
| DRD4 VNTR | 7R homozygous (8, 3%); 7R heterozygous (62, 33%); non-7R/non-7R (161, 64%) | 0.53 |
| Taq IA (rs1800497) | A1/A1 (12, 5%); A1/A2 (74, 29%); A2/A2 (165, 66%) | 0.33 |
| COMT (rs4680) | A/A (58, 23%); A/G (131, 52%); G/G (62, 25%) | 0.48 |

Criteria for Hardy Weinberg Equilibrium were met for the five genes.

https://doi.org/10.1371/journal.pone.0177344.t002

| Table 3. Mean outcome measures of the Bayley tests at 36 months. |
|-------------------------------------|
| **Outcome** | **SGA** | **AGA** | **LGA** | **$P$ value** |
| Total Behavioral Scale | 122.44(6.25) | 123.22(6.15) | 125.19(4.39) | 0.22 |
| Motor Developmental Index (PDI) | 99.04(11.50) | 100.99(12.77) | 103.67(14.16) | 0.35 |
| Mental Developmental Index (MDI) | 96.96(11.50) | 98.47(10.43) | 99.10(10.41) | 0.63 |

Data are expressed as Mean (SD). There were no statistically significant differences observed between the groups.

https://doi.org/10.1371/journal.pone.0177344.t003
statistically significant differences observed between the groups in the three domains of Bayley; moreover, there were no significant interactions between the neonatal groups and the dopamine genetic score [Total Behavioral scale: estimated $\beta = -0.47$, $p = 0.21$ for SGA vs AGA; estimated $\beta = 0.22$, $p = 0.89$ for LGA vs. AGA; PDI: estimated $\beta = 2.3$, $p = 0.36$ for SGA vs AGA; estimated $\beta = -6.29$, $p = 0.08$ for LGA vs. AGA; MDI: estimated $\beta = 1.16$, $p = 0.6$ for the comparison between SGA vs AGA and estimated $\beta = -3.62$, $p = 0.23$ for LGA vs. AGA].

However, when taking different BWR cut-offs, varying from 0.7 to 1.0 to define the SGA group or from 1.01 to 1.2 to define the LGA group, we observe certain significant interactions for specific outcomes (see Fig 2, S# Videos and S# Figs).

The different graphs on Fig 2 plot a range of SGA cut-offs on the x axis, and LGA cut-offs on the y axis, depicting the level of significance for the interaction between BWR and the dopamine genetic score if those cut off were chosen. Black signs show interactions that are not significant ($p > 0.05$), red signs represent interactions that are statistically significant ($p < 0.05$) and green display the regions where the comparison included a group with less than 15 participants.

Fig 2A/2B, S1 Video and S1 Fig, show the results for the Total Behavioral Score from Bayley. We can see that while there were no significant interactions between BWR and the dopamine genetic score when comparing LGA to AGA (2B), there was a diverse range of cut-offs defining the SGA group that represent significant differences between SGA and AGA for the effect of dopamine genetic score on the outcome (2A). In other words, if any cut-off within the “red” range is taken to define the SGA group, there will be a significant interaction between BWR and the dopamine genetic score on the Total Behavioral score. For example, if taking 0.8 as the cut-off “A” (children with BWR $\leq 0.8$ are considered SGA) and 1.1 as the cut-off “B” (children with BWR between 0.8 and 1.1 are AGA and higher than 1.1 are LGA), as the dopamine genetic score increases (representing higher dopaminergic function), the Total Behavioral Score decreases in the SGA group [estimated $\beta = -4.21$, $p = 0.008$], but the slopes for both AGA [estimated $\beta = -0.79$, $p = 0.16$] and LGA groups [estimated $\beta = -1.57$, $p = 0.18$] are not statistically significant.

Fig 2C/2D, S2 Video and S2 Fig show the results for the Motor Developmental Index (PDI) from Bayley. We see that while there were no significant interactions between BWR and the dopamine genetic score when comparing SGA to AGA (2C), there was a range of cut-offs defining the LGA group representing significant differences between LGA and AGA for the effect of dopamine genetic score on the outcome (2D). Specifically, if any cut-off within the red range is taken to define the LGA group, there will be a significant interaction between BWR and the dopamine genetic score on PDI. Using the same example, when taking 0.8 as the cut-off “A” and 1.1 as the cut-off “B”, as the dopamine genetic score increases, PDI decreases in the LGA group [estimated $\beta = -6.51$, $p = 0.009$], but the slopes for both AGA [estimated $\beta = 1.25$, $p = 0.28$] and SGA groups [estimated $\beta = -1.93$, $p = 0.55$] are not statistically significant.

Fig 2E/2F, S3 Video and S3 Fig show the results for the Mental Developmental Index (MDI) from Bayley. For any cut-offs chosen as “A” and “B”, there were no statistically significant interactions found between BWR and the dopamine genetic score. Although a few statistically significant points are seen in the figures, these are most likely due to artifact than to true results.

The videos show the different “B” cut-offs in the x axis for a fixed cut-off “A” in each frame. In the y axis, the estimated beta coefficients for the interaction between BWR and the dopamine genetic score are displayed. AGA group was considered the reference group in all the analysis. Circles represent the difference in the dopamine genetic score slopes between SGA and AGA groups, and the triangles display the difference between LGA and AGA groups. Video 1 shows data for Total Behavioral Score, video 2 for PDI and video 3 for MDI scores. It is possible to observe that, according to our hypothesis, birth weight moderates the association between the multilocus genetic score reflecting dopaminergic function and development at 3
Fig 2. Estimated $\beta$ for dopamine multilocus score. A range of SGA cut-offs is shown on the x axis, and LGA cut-offs are depicted on the y axis. Black signs show interactions that are not significant ($p > 0.05$), red signs represent interactions that are statistically significant ($p < 0.05$) and green display the regions where the comparison included a group with less than 15 participants. A and B: Total Behavioral Score; C and D: Motor Developmental Index (PDI); E and F: Mental Developmental Index (MDI) from Bayley. A, C and E are comparisons between SGA and AGA, while B, D and F are comparison between LGA and AGA.

https://doi.org/10.1371/journal.pone.0177344.g002
years of age, but this is limited to and variable across the specific Bayley domains, as well as with the different cut-offs defining SGA and LGA.

Discussion
This study exemplifies how limited is the concept of long-term vulnerability defined by standard birth weight cut-offs currently used in Pediatrics. More specifically, we described here that birth weight moderates the association between a genetic score reflecting dopaminergic function and development at 3 years of age, but this is specific to certain developmental domains, and varies according to the different cut-offs defining SGA and LGA.

For a certain range of cut-offs on BWR, the results showed significant differences comparing SGA and AGA on the Total Behavioral scale. In addition, LGA and AGA groups significantly differed in the Motor Developmental Index using a diverse range of “B” cut-offs. These findings agree with the literature showing that both low and high birth weight children have increased risk for several conditions during the life course [3–14], but not necessarily the same poor outcomes are expected for both groups.

The novelty aspect of the current study lies in the fact that, using the classic cut-offs to define SGA and LGA, these interactions would not be perceived. This highlights the discrete line that separates those at risk versus those that are not, as well as the specificity of this line according to the studied outcome. From a clinical standpoint, this means that there is a fine balance between a) being too inclusive to select a wide variety of children for close follow up during childhood, increasing the health care costs, the burden of repeated assessments as well as the stigma of being “fragile” or b) being too strict in the definition of the group to be followed, and therefore missing the opportunity for screening those at risk and for establishing preventive or intervention measures. Although we do not provide a final definition, we highlight the importance of research in this field and the urge for the development of algorithms to be applied very early in life—potentially at birth—that could predict risk for disease based on prenatal history.

It is important to mention that studies involving gene versus environment interactions can be very challenging. It is hard to deal with the multitude of variation in the environment (e.g. home, school, society) and how these several “layers” influence the risk for disease [58]. In addition, single candidate gene studies are obviously limited considering the whole genome richness, therefore methods involving a pathway-based strategy, like the one used in this study, may be physiologically more relevant.

The significant interactions between fetal growth and the DA multilocus on the Motor domain of the Bayley II scores are not surprising considering that DA is in close relationship to movement disorders such as Parkinson and Huntington’s diseases [39]. Similarly to what occurs in these diseases, unbalances in basal ganglia pathways, which are largely regulated by DA, are likely implicated in the more subtle changes seen in gross and fine motor skills evaluated through the Bayley-II.

The association between DA and behavioral aspects is also clear in the literature. There is consistent evidence that some dopamine gene polymorphisms are involved in the etiology of ADHD, one of the most prevalent childhood psychiatric disorder [60, 61]. The DA hypothesis is supported by animal, pharmacological, brain imaging and genetic studies [62]. Alterations in the mesocorticolimbic pathway correlate with impulsivity [63] and variations in selective attention [64], while the nigrostriatal pathway is associated with hyperactivity [65].

The DA system seems to be particularly vulnerable to variations in the environment [58, 66]. Research suggests that genes may have been naturally selected as a form to bet-hedge against an uncertain future [67], both for conditional and fixed health strategies. In the case of DA-related genes and specifically in the example illustrated in our study, fetal growth could
signal the quality of the uterine environment, with both aberrant extremes (poor or excessive growth) seen as unfavorable conditions and therefore leading to worse outcomes [68].

One of the limitations of this study lies on the fact that we were not able to precise which cut-offs would be optimal to define developmental vulnerability according to the dopamine genetic score. However, this would be a rather specific information, pending external validity. In addition, our multilocus score considers that "risk" has the same weight across the different polymorphisms, as opposed to characterizing them in terms of a particular odds ratio for a certain outcome. One of the reasons for that is to consider that 2 out of the 5 genetic polymorphisms from our score are VNTRs, and these are not included in Genome Wide Association Studies (GWAS). As a long list of scientific evidence has shown that the genetic variation involving these polymorphisms plays an important role in modifying neurocognitive outcomes, we assume that their relevance cannot be denied [69]. In addition, as highlighted above, dopamine genes could function as "plasticity genes", having their association with the outcome changing directionality in terms of risk/protection according to variations in the environment (in our case, the fetal environment)[58, 66]. We believe that message of awareness regarding the dynamic relationship between different birth weight cut-offs and long-term risk, as well as about the specificity of this relationship to certain outcomes is relevant and could be applicable in other contexts.

In summary, the classic birth weight cut-offs to define SGA and LGA newborns should be seen with caution, as depending on the outcome in question, the protocols for long-term follow up could be either too inclusive—therefore most costly, or unable to screen true vulnerabilities—and therefore ineffective to establish early interventions and primary prevention. Our study suggests that the established cut-offs should not be used blindly; we favor a personalized approach to pediatric follow up, considering the different aspects of the child's history (ex.: fetal growth, birth and neonatal trajectory, family history, current development, etc.) as well as highlight the importance of close and repeated developmental assessments during childhood.

**Supporting information**

S1 Fig. Still image of the video showing the results for the Total Behavioral Score. (TIF)

S2 Fig. Still image of the video showing the results for the Motor Developmental Index. (TIF)

S3 Fig. Still image of the video showing the results for the Mental Developmental Index. (TIF)

S1 Video. Video showing the results for the Total Behavioral Score. (MP4)

S2 Video. Video showing the results for the Motor Developmental Index. (MP4)

S3 Video. Video showing the results for the Mental Developmental Index. (MP4)

**Acknowledgments**

This work was funded by the Canadian Institutes of Health Research (CIHR), the JPB Foundation and the Sackler Institute. These sponsors had no influence on the study design and conduct of the study; collection, management, analysis, and interpretation of the data; and
preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Bischoff AR wrote the first draft of the manuscript, and although we had financial support from these granting agencies for the project no honorarium, grant, or other form of payment was given to anyone to produce specifically this manuscript. The authors have no conflicts of interest to declare.

**Author Contributions**

**Conceptualization:** MJM MS PPS.

**Data curation:** HG IP EL.

**Formal analysis:** EL ARB IP PPS.

**Funding acquisition:** JD MJM JLK.

**Investigation:** PPS ARB IP EL.

**Methodology:** ARB EL IP KJO PPS.

**Project administration:** HG KJO JD.

**Resources:** JD MJM.

**Software:** EL IP.

**Supervision:** PPS KJO MJM.

**Validation:** EL IP.

**Visualization:** EL IP.

**Writing – original draft:** ARB PPS IP.

**References**

1. Barker DJ, Eriksson JG, Forsén T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002; 31(6):1235–9. PMID: 12540728

2. Silveira PP, Portella AK, Goldani MZ, Barbieri MA. Developmental origins of health and disease (DOHaD). J Pediatr (Rio J). 2007; 83(6):494–504.

3. Eriksson JG, Forsén T, Tuomilehto J, Jaddoe VW, Osmond C, Barker DJ. Effects of size at birth and childhood growth on the insulin resistance syndrome in elderly individuals. Diabetologia. 2002; 45(3):342–8. https://doi.org/10.1007/s00125-001-0757-6 PMID: 11914739

4. Eriksson JG, Kajantie E, Lamm M, Osmond C, Barker DJ. Small head circumference at birth and early age at adiposity rebound. Acta Physiol (Oxf). 2014; 210(1):154–60.

5. Barker DJ, Osmond C, Forsén T, Kajantie E, Eriksson JG. Trajectories of growth among children who have coronary events as adults. N Engl J Med. 2005; 353(17):1802–9. https://doi.org/10.1056/NEJMoa044160 PMID: 16251536

6. Costello EJ, Worthman C, Erkanli A, Angold A. Prediction from low birth weight to female adolescent depression: a test of competing hypotheses. Arch Gen Psychiatry. 2007; 64(3):338–44. https://doi.org/10.1001/archpsyc.64.3.338 PMID: 17339522

7. Hack M, Youngstrom EA, Cartar L, Schluchter M, Taylor HG, Flannery D, et al. Behavioral outcomes and evidence of psychopathology among very low birth weight infants at age 20 years. Pediatrics. 2004; 114(4):932–40. https://doi.org/10.1542/peds.2003-1017-L PMID: 15466087

8. van der Reijden-Lakeman IE, de Sonneville LM, Swaab-Barneveld HJ, Slijper FM, Verhulst FC. Evaluation of attention before and after 2 years of growth hormone treatment in intrauterine growth retarded children. J Clin Exp Neuropsychol. 1997; 19(1):101–18. https://doi.org/10.1080/01688639708403840 PMID: 9071645
9. Lahti M, Eriksson JG, Heinonen K, Kajantie E, Lahti J, Wahlbeck K, et al. Late preterm birth, post-term birth, and abnormal fetal growth as risk factors for severe mental disorders from early to late adulthood. Psychol Med. 2015; 45(5):985–99. https://doi.org/10.1017/S0033291714001998 PMID: 25191989

10. Chiavaroli V, Marcovceco ML, de Giorgis T, Diesse L, Chiarelli F, Mohn A. Progression of cardio-metabolic risk factors in subjects born small and large for gestational age. PloS one. 2014; 9(8):e104278. https://doi.org/10.1371 journal.pone.0104278 PMID: 25117750

11. Herva A, Pouta A, Hakko H, Laksy K, Joukamaa M, Veijola J. Birth measures and depression at age 31 years: the Northern Finland 1966 Birth Cohort Study. Psychiatry Res. 2008; 160(3):263–70. https://doi.org/10.1016/j.psychres.2007.07.020 PMID: 18710786

12. Hultman CM, Ohman A, Cnattingius S, Wieselgren IM, Lindstrom LH. Prenatal and neonatal risk factors for schizophrenia. The British journal of psychiatry: the journal of mental science. 1997; 170:128–33.

13. Bersani G, Manuali G, Ramieri L, Taddei I, Bersani I, Conforti F, et al. The potential role of high or low birthweight as risk factor for adult schizophrenia. J Perinat Med. 2007; 35(2):159–61. https://doi.org/10.1515/JPM.2007.021 PMID: 17302511

14. Colman I, Ploubidis GB, Wadsworth ME, Jones PB, Croudace TJ. A longitudinal typology of symptoms of depression and anxiety over the life course. Biol Psychiatry. 2007; 62(11):1265–71. https://doi.org/10.1016/j.biopsych.2007.05.012 PMID: 17692292

15. Buschgens CJ, Swinkels SH, van Aken MA, Ormel J, Verhulst FC, Buitelaar JK. Externalizing behaviors in preadolescents: familial risk to externalizing behaviors, prenatal and perinatal risks, and their interactions. European child & adolescent psychiatry. 2009; 18(2):65–74.

16. Grissom NM, Reyes TM. Gestational overgrowth and undergrowth affect neurodevelopment: similarities and differences from behavior to epigenetics. International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience. 2013; 31(6):406–14.

17. Levine TA, Grunau RE, McAuliffe FM, Foran A, Alderdice FA. Early childhood neurodevelopment after intrauterine growth restriction: a systematic review. Pediatrics. 2015; 135(1):126–41. https://doi.org/10.1542/peds.2014-1143 PMID: 25548332

18. Padilla N, Falcon C, Sanz-Cortes M, Figueras F, Bargallo N, Crispi F, et al. Differential effects of intrauterine growth restriction on brain structure and development in preterm infants: a magnetic resonance imaging study. Brain Res. 2011; 1382:98–108. https://doi.org/10.1016/j.brainres.2011.01.032 PMID: 21255560

19. Leitner Y, Fattal-Valevski A, Geva R, Bassan H, Posner E, Kutai M, et al. Six-year follow-up of children with intrauterine growth retardation: long-term, prospective study. J Child Neurol. 2000; 15(12):781–6. https://doi.org/10.1177/088307380001501202 PMID: 11198491

20. Esteban FJ, Padilla N, Sanz-Cortes M, de Miras JR, Bargallo N, Villoslada P, et al. Fractal-dimension analysis detects cerebral changes in preterm infants with and without intrauterine growth restriction. NeuroImage. 2010; 53(4):1225–32. https://doi.org/10.1016/j.neuroimage.2010.07.019 PMID: 20633658

21. Victora CG, Adair L, Fall C, Hallal PC, Martorell R, Richter L, et al. Maternal and child undernutrition: consequences for adult health and human capital. Lancet. 2008; 371(9609):340–57. https://doi.org/10.1016/S0140-6736(00)08985-2 PMID: 18206223

22. Daraki V, Roumeliotaki T, Koutra K, Georgiou V, Kampouri M, Kyriklaki A, et al. Effect of parental obesity and gestational diabetes on child neuropsychological and behavioral development at 4 years of age: the Rhea mother-child cohort, Crete, Greece. Eur Child Adolesc Psychiatry. 2017.

23. Moore GS, Kneitel AW, Walker CK, Gilbert WM, Xing G. Autism risk in small- and large-for-gestational-age infants. Am J Obstet Gynecol. 2012; 206(4):314 e1–9.

24. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol. 1989; 40:191–225. https://doi.org/10.1146/annurev.psych.40.020189.001203 PMID: 2648975

25. Beninger RJ. The role of dopamine in locomotor activity and learning. Brain Res. 1983; 287(2):173–96. PMID: 6357357

26. Yue JK, Winkler EA, Rick JW, Burke JF, McAllister TW, Oh SS, et al. DRD2 C957T polymorphism is associated with improved 6-month verbal learning following traumatic brain injury. Neurogenetics. 2016.

27. Tovo-Rodrigues L, Rohde LA, Menezes AM, Polanczyk GV, Kieling C, Genro JP, et al. DRD4 rare variants in Attention-Deficit/Hyperactivity Disorder (ADHD): further evidence from a birth cohort study. PLoS One. 2013; 8(12):e85164. https://doi.org/10.1371/journal.pone.0085164 PMID: 24391992

28. Gasso P, Ortiz AE, Mas S, Morer A, Calvo A, Bargallo N, et al. Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder. J Affect Disord. 2015; 186:284–92. https://doi.org/10.1016/j.jad.2015.07.035 PMID: 26254621
29. Cheng J, Wang Y, Zhou K, Wang L, Li J, Zhuang Q, et al. Male-specific association between dopamine receptor D4 gene methylation and schizophrenia. PLoS One. 2014; 9(2):e89128. https://doi.org/10.1371/journal.pone.0089128 PMID: 24586542

30. Hosp JA, Luft AR. Dopaminergic Meso-Cortical Projections to M1: Role in Motor Learning and Motor Cortex Plasticity. Frontiers in Neurology. 2013; 4.

31. Qian Y, Chen M, Forssberg H, Diaz Heijtz R. Genetic variation in dopamine-related gene expression influences motor skill learning in mice. Genes Brain Behav. 2013; 12(6):604–14. https://doi.org/10.1111/gbb.12062 PMID: 23819855

32. Kordas K, Ettinger AS, Bellinger DC, Schnaas L, Tellez Rojo MM, Hernandez-Avila M, et al. A dopamine receptor (DRD2) but not dopamine transporter (DAT1) gene polymorphism is associated with neurocognitive development of Mexican preschool children with lead exposure. J Pediatr. 2011; 159(4):638–43. https://doi.org/10.1016/j.jpeds.2011.03.043 PMID: 21592505

33. Zhang S, Zhang M, Zhang J. An Exploratory Study on DRD2 and Creative Potential. Creativity Research Journal. 2014; 26(1):115–23.

34. Reuter M, Roth S, Holve K, Hennig J. Identification of first candidate genes for creativity: a pilot study. Brain research. 2006; 1069(1):190–7. https://doi.org/10.1016/j.brainres.2005.11.046 PMID: 16403463

35. Alves MB, Molle RD, Desai M, Ross MG, Silveira PP. Increased Palatable Food Intake and Response to Food Cues in Intrauterine Growth-Restricted Rats Are Related to Tyrosine Hydroxylase Content in the Orbitofrontal Cortex and Nucleus Accumbens. Behavioural brain research. 2015.

36. Dalle Molle R, Laureano DP, Alves MB, Reis TM, Desai M, Ross MG, et al. Intrauterine growth restriction increases the preference for palatable foods and affects sensitivity to food rewards in male and female adult rats. Brain Res. 2015; 1618:41–9. https://doi.org/10.1016/j.brainres.2015.05.019 PMID: 26006109

37. Vucetic Z, Totoki K, Schoch H, Whitaker KW, Hill-Smith T, Lucki I, et al. Early life protein restriction alters dopamine circuitry. Neuroscience. 2010; 168(2):359–70. https://doi.org/10.1016/j.neuroscience.2010.04.010 PMID: 20394806

38. Bruder GE, Keilp JG, Xu H, Shikhman M, Schori E, Gorman JM, et al. Catechol-O-methyltransferase (COMT) genotype and working memory: associations with differing cognitive operations. Biol Psychiatry. 2005; 58(11):901–7. https://doi.org/10.1016/j.biopsych.2005.05.010 PMID: 16034133

39. Sheidrick AJ, Krug A, Markov V, Leube D, Michel TM, Zerres K, et al. Effect of COMT val158met genotype on cognition and personality. Eur Psychiatry. 2008; 23(6):385–9. https://doi.org/10.1016/j.eurpsy.2008.05.002 PMID: 18755576

40. Abulseoud OA, Ramsay H, Barnett JH, Miettunen J, Makkalä S, Makki P, et al. Association between Dopamine Receptor D2 (DRD2) Variations rs6277 and rs1800497 and Cognitive Performance According to Risk Type for Psychosis: A Nested Case Control Study in a Finnish Population Sample. PLoS one. 2015; 10(6):e0127602. https://doi.org/10.1371/journal.pone.0127602 PMID: 26114663

41. Maitra S, Sarkar K, Ghosh P, Karmakar A, Bhattacharjee A, Sinha S, et al. Potential contribution of dopaminergic gene variants in ADHD core traits and co-morbidity: a study on eastern Indian probands. Cellular and molecular neurobiology. 2014; 34(4):549–64. https://doi.org/10.1007/s10571-014-0038-9 PMID: 24585059

42. Altink ME, Rommelse NN, Slaats-Wijmels DI, Vasquez AA, Franke B, Buschgens CJ, et al. The dopamine receptor D4 7-repeat allele influences neurocognitive functioning, but this effect is moderated by age and ADHD status: an exploratory study. World J Biol Psychiatry. 2012; 13(4):293–305. https://doi.org/10.3109/15622975.2011.585822 PMID: 22111665

43. Szekely A, Balota DA, Duchek JM, Nemoda Z, Zervczyk A, Sasvari-Szekely M. Genetic factors of reaction time performance: DRD4 7-repeat allele associated with slower responses. Genes, Brain and Behavior. 2011; 10(2):129–36.

44. Garcia-Garcia M, Barcelo F, Clemente IC, Escera C. The role of the dopamine transporter DAT1 genotype on the neural correlates of cognitive flexibility. The European journal of neuroscience. 2010; 31(4):754–60. https://doi.org/10.1111/j.1460-9568.2010.07102.x PMID: 20141527

45. Goel N, Mata R, Hau R, Papassotropoulos A, Hertwig R. DAT1 Polymorphism Is Associated with Risk Taking in the Balloon Analogue Risk Task (BART). PloS one. 2012; 7(6):e39135. https://doi.org/10.1371/journal.pone.0039135 PMID: 22723947

46. O'Donnell KA, Gaudreau H, Colalillo S, Steiner M, Atkinson L, Moss E, et al. The maternal adversity, vulnerability and neurodevelopmental project: theory and methodology. Can J Psychiatry. 2014; 59(9):497–508. https://doi.org/10.1177/07067437145590906 PMID: 25566695

47. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001; 108(2):E35. PMID: 11483945
48. Davis C, Loxton NJ, Levitan RD, Kaplan AS, Carter JC, Kennedy JL. ‘Food addiction’ and its association with a dopaminergic multilocus genetic profile. Physiol Behav. 2013; 118:63–9. https://doi.org/10.1016/j.physbeh.2013.05.014 PMID: 23680433

49. Stice E, Yokum S, Burger K, Epstein L, Smolen A. Multilocus genetic composite reflecting dopamine signaling capacity predicts reward circuitry responsivity. J Neurosci. 2012; 32(29):10093–100. https://doi.org/10.1523/JNEUROSCI.1506-12.2012 PMID: 22815523

50. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry. 1991; 48(7):648–54. PMID: 2069496

51. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999; 4(3):290–6. PMID: 10395223

52. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem. 1995; 65(3):1157–65. PMID: 7643093

53. Mill J, Asherson P, Browes C, D’Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3’ UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet. 2002; 114(8):975–9. https://doi.org/10.1002/ajmg.b.10948 PMID: 12457396

54. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996; 6(3):243–50. PMID: 8807664

55. Bayley N. Bayley Scales of Infant Development. 2 ed: Psychological Corporation; 1993.

56. R CT. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.

57. Low income cut offs for 2005 and low income measures for 2004. Statistics Canada2006.

58. Dalle Molle R, Fatemi H, Dagher A, Levitan RD, Silveira PP, Dube L. Gene and environment interaction: Is the differential susceptibility hypothesis relevant for obesity? Neurosci Biobehav Rev. 2017; 73:326–39. https://doi.org/10.1016/j.neubiorev.2016.12.028 PMID: 28024828

59. Young AB, Penney JB. Neurochemical anatomy of movement disorders. Neurol Clin. 1984; 2(3):417–33. PMID: 6152481

60. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009; 126(1):51–90. https://doi.org/10.1007/s00439-009-0694-x PMID: 19506906

61. ElBaz Mohamed F, Kamal TM, Zahra SS, Khfagy MA, Youssef AM. Dopamine D4 Receptor Gene Polymorphism in a Sample of Egyptian Children With Attention-Deficit Hyperactivity Disorder (ADHD). J Child Neurol. 2016.

62. Genro JP, Kieling C, Rohde LA, Hutz MH. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses. Expert Rev Neurther. 2010; 10(4):587–601. https://doi.org/10.1586/ern.10.17 PMID: 20967210

63. Cardinal RN, Winstanley CA, Robbins TW, Everitt BJ. Limbic corticostriatal systems and delayed reinforcement. Ann N Y Acad Sci. 2004; 1021:33–50. https://doi.org/10.1196/annals.1308.004 PMID: 15281872

64. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Animal models of attention-deficit hyperactivity disorder. Brain Res Brain Res Rev. 2003; 42(1):1–21. PMID: 12668268

65. Kadesjo B, Gillberg C. Developmental coordination disorder in Swedish 7-year-old children. J Am Acad Child Adolesc Psychiatry. 1999; 38(7):820–8. https://doi.org/10.1097/00004583-199907000-00011 PMID: 10405499

66. Silveira PP, Gaudreau H, Atkinson L, Fleming AS, Sokolowsk MB, Steiner M, et al. Genetic Differential Susceptibility to Socioeconomic Status and Childhood Obesogenic Behavior. JAMA Pediatrics. 2016.

67. Rowe DC, Vazsonyi AT, Figueredo AJ. Mating-effort in adolescence: A conditional or alternative strategy. Pers Indiv Differ. 1997; 23(1):105–15.

68. Belsky J, Jonassaint C, Pluess M, Stanton M, Brunnett B, Williams R. Vulnerability genes or plasticity genes? Molecular psychiatry. 2009; 14(8):746–54. https://doi.org/10.1038/mp.2009.44 PMID: 19455150

69. Brookes KJ. The VNTR in complex disorders: The forgotten polymorphisms? A functional way forward? Genomics. 2013; 101(5):273–81. https://doi.org/10.1016/j.ygeno.2013.03.003 PMID: 23517681